Micro-Dystrophin AAV Vectors With Genotype-Guided DMD Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating Duchenne muscular dystrophy using AAV vectors are inadequate, particularly in identifying patient populations that would benefit from or be contraindicated for gene therapy, and there is a need for improved methods to express micro-dystrophin in skeletal muscles to prevent fibrosis and increase muscle strength.
Innovation Solution
Production of recombinant AAV vectors expressing human micro-dystrophin in adherent mammalian cells through a suspension seed process, including specific nucleotide sequences and promoter sequences, followed by purification steps, and administration to patients genotyped for DMD gene mutations to optimize treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If AAV vectors are used to deliver micro-dystrophin gene, then muscle strength and function are improved, but fibrosis and muscle degeneration occur due to membrane fragility
Solution Approach 1:
The patent applies preliminary action by administering AAV-mediated micro-dystrophin gene therapy before severe fibrosis and muscle degeneration occur. The therapy prevents membrane fragility and sarcolemmal tears proactively, stopping the cycle of muscle injury and fibrosis before it progresses to irreversible damage, thereby improving muscle strength while preventing harmful fibrotic changes
2Reliability
If micro-dystrophin is expressed to stabilize muscle membrane, then muscle function improves, but current methods lack precision in identifying suitable patient populations
Solution Approach 1:
The patent applies feedback by implementing genotype-guided patient selection that provides precise information about which patients will benefit from micro-dystrophin therapy. By analyzing specific DMD gene mutations and their compatibility with micro-dystrophin expression, the system feedbacks treatment suitability information, ensuring reliable treatment outcomes only for appropriate patient populations while avoiding ineffective treatments
3Productivity
If AAV vector production is scaled up for clinical use, then treatment availability increases, but manufacturing complexity and purification challenges increase
Solution Approach 1:
The patent applies segmentation by dividing the AAV vector production process into distinct modular stages: cell culture, transfection, viral assembly, harvesting, and purification. This segmented approach allows each stage to be optimized independently and scaled separately, increasing overall productivity while managing manufacturing complexity through systematic organization of production steps
Data Source
AI summary
The present disclosure provides gene therapy vectors, such as recombinant adeno-associated virus (rAAV) for expressing a human micro-dystrophin gene. The present disclosure also provides compositions and methods of using these rAAV to treat muscular dystrophy, such as, e.g., Duchenne Muscular Dystrophy. The present disclosure also provides genotyping a subject's DMD gene to determine if rAAV gene therapy should be contraindicated.